Novo Nordisk’s new GLP-1 pill for obesity, Wegovy, had an encouraging start in the US, with 3,100 prescriptions filled in the first week of launch. Shares rose over 5% on this news, boosting the company’s hopes of gaining market share from rival Eli Lilly. Wegovy’s success may face challenges due to dietary restrictions.

Read more at CNBC: Novo Nordisk shares rise after Wegovy obesity pill launch